regulatoryhigh confidence

FDA Approves Durvalumab with Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer

|Cancer Breakthroughs

The FDA listed an approval dated November 13, 2026 for durvalumab in combination with enfortumab vedotin-ejfv for muscle-invasive bladder cancer. Details beyond the FDA notification listing were not independently verified.

Media

FDA oncology approval notification
FDA oncology approval notification — U.S. FDA

Sources

View full Cancer Breakthroughs dashboard